Related Experiment Video
Updated: Feb 7, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
Published on: August 11, 2008
Management of Multidrug-Resistant Tuberculosis
Charles L Daley1,2,3, Jose A Caminero4,5
1Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, Colorado.
Drug-resistant tuberculosis (TB) is a growing global health crisis. This review updates management strategies for multidrug-resistant TB (MDR-TB) and rifampin-resistant TB (RR-TB), including shorter regimens and new drugs.
Area of Science:
- Infectious Diseases
- Microbiology
- Public Health
Background:
- Drug-resistant strains of Mycobacterium tuberculosis present a significant challenge to global tuberculosis control.
- Inappropriate treatment and transmission have led to alarming rates of drug-resistant tuberculosis, with an estimated 600,000 cases of multidrug-resistant tuberculosis (MDR-TB)/rifampin-resistant (RR) tuberculosis in 2016.
- Extensively drug-resistant strains have emerged in 123 countries, and only 22% of MDR-TB cases are currently receiving treatment.
Purpose of the Study:
- To review the current management of multidrug-resistant/rifampin-resistant tuberculosis (MDR/RR-TB).
- To provide updated recommendations on treatment strategies for MDR/RR-TB.
- To highlight the role of shorter course regimens and novel drugs in combating drug-resistant tuberculosis.
Main Methods:
- Literature review of existing studies and guidelines on MDR/RR-TB management.
- Analysis of World Health Organization (WHO) estimates and global surveillance data.
- Synthesis of current evidence on therapeutic interventions for drug-resistant tuberculosis.
Main Results:
- MDR-TB and RR-TB are significant global health concerns, affecting both new and retreatment tuberculosis cases.
- The emergence of extensively drug-resistant strains necessitates urgent attention and revised treatment approaches.
- Limited access to current MDR-TB therapy underscores the need for improved treatment accessibility and efficacy.
Conclusions:
- Effective management of MDR/RR-TB requires updated therapeutic strategies, including the judicious use of shorter regimens.
- The integration of new anti-tuberculosis drugs is crucial for improving treatment outcomes in patients with drug-resistant strains.
- Continued global efforts in surveillance, treatment, and prevention are essential to control the spread of drug-resistant tuberculosis.
More Related Videos
09:29In Vivo Investigation of Antimicrobial Blue Light Therapy for Multidrug-resistant Acinetobacter baumannii Burn Infections Using Bioluminescence Imaging
Published on: April 28, 2017
07:35Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray
Published on: April 25, 2014
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Resistivity
Resistance
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories: